Retrospective Cohort Study: Except for Rituximab, most immunosuppressive medicines were not associated with increased risk of mechanical ventilation or death in patients hospitalized with Covid-19.

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative – The Lancet Rheumatology

Commentaries:

What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology

Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds – Johns Hopkins University Bloomberg School of Public Health

Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP

Commentary on Twitter

NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins pic.twitter.com/NqlttjGrpj

— The Lancet Rheumatology (@TheLancetRheum) November 16, 2021